What is it about?
This 12-week double-blind study compared the effectiveness and safety of two different inhalers to treat COPD. The study's goal was to prove that Gylcopyrroniyum a new pharmaceutical is just as effective as the widely prescribed Trotropium. Both were once-daily medications that showed comparable levels of safety and efficacy after 12 weeks. Gycopyrronium did show a faster onset on day one and had improved the reduction of self-reported COPD symptoms.
Featured Image
Photo by Glenn Carstens-Peters on Unsplash
Why is it important?
With few treatment options for COPD the testing of novel treatments helps to expand care options and as shown in this study can offer improvements.
Perspectives
After the GLOW 1,2,3, studies GLOW5 offers an unbiased study powered to show statistical non-inferiority of Gycopyrronium to Tiotropium.
Professor Kenneth R Chapman
University of Toronto
Read the Original
This page is a summary of: A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study, BMC Pulmonary Medicine, January 2014, Springer Science + Business Media,
DOI: 10.1186/1471-2466-14-4.
You can read the full text:
Resources
Contributors
The following have contributed to this page
